Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465958 | 0.92 | CNR1 (0.69) | CNR1 | |
| SCHEMBL2704945 | 0.92 | CNR1 (0.67) | CNR1 | |
| SCHEMBL5773432 | 0.80 | CNR1 (0.62) | CNR1 | |
| SCHEMBL4677623 | 0.80 | DHODH (0.52) | CNR1 | |
| SCHEMBL4453192 | 0.79 | CNR1 (0.64) | CNR1 | |
| SCHEMBL4463174 | 0.79 | CNR1 (0.64) | CNR1 | |
| SCHEMBL2113992 | 0.79 | CNR1 (0.51) | CNR1 | |
| SCHEMBL4252468 | 0.78 | CNR1 (0.61) | CNR1 | |
| SCHEMBL3820443 | 0.78 | CNR1 (0.48) | CNR1 | |
| SCHEMBL30712642 | 0.77 | CNR1 (0.66) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093484-A1 | 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093484-A1 | 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators | CNR2, CNR1, FAAH | CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.